Peripheral T follicular helper cells are the major HIV reservoir within central memory CD4 T cells in peripheral blood from chronically HIV-infected individuals on combination antiretroviral therapy

Journal of Virology

Volumn 90, Issue 6, 2016, Pages 2718-2728

  Pallikkuth, Suresh ^a   Sharkey, Mark ^a   Babic, Dunja Z ^a   Gupta, Sachin ^a   Stone, Geoffrey W ^a   Fischl, Margaret A ^a   Stevenson, Mario ^a   Pahwa, Savita ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; EMTRICITABINE; GAG PROTEIN; HLA DR ANTIGEN; LOPINAVIR PLUS RITONAVIR; RALTEGRAVIR; TENOFOVIR DISOPROXIL; VIRUS DNA; ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; EPISOME; FLOW CYTOMETRY; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LONG TERMINAL REPEAT; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VIRUS CARRIER; VIRUS REACTIVATION; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; MIDDLE AGED; PILOT STUDY; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; PROVIRUS; VIROLOGY; VIRUS ACTIVATION;

ADULT; ANTI-RETROVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; PILOT PROJECTS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; PROVIRUSES; T-LYMPHOCYTE SUBSETS; VIRUS ACTIVATION;

EID: 84961161685     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02883-15     Document Type: Article

References (56)

1. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M, Ho DD. 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387:188-191. http://dx.doi.org/10.1038/387188a0.
2. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586. http://dx.doi.org/10.1126/science.271.5255.1582.
3. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, Kempf DJ, Mellors JW, Coffin JM, King MS. 2008. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 105:3879-3884. http://dx.doi.org/10.1073/pnas.0800050105.
4. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, Cranmer L, O'Shea A, Callender M, Spivak A, Brennan T, Kearney MF, Proschan MA, Mican JM, Rehm CA, Coffin JM, Mellors JW, Siliciano RF, Maldarelli F. 2009. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A 106:9403-9408. http://dx.doi.org/10.1073/pnas.0903107106.
5. Gandhi RT, Coombs RW, Chan ES, Bosch RJ, Zheng L, Margolis DM, Read S, Kallungal B, Chang M, Goecker EA, Wiegand A, Kearney M, Jacobson JM, D'Aquila R, Lederman MM, Mellors JW, Eron JJ. 2012. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr 59:229-235. http://dx.doi.org/10.1097/QAI.0b013e31823fd1f2.
6. McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, Palmer S, McNulty S, Metcalf JA, Acosta E, Rehm C, Coffin JM, Mellors JW, Maldarelli F. 2010. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 50:912-919. http://dx.doi.org/10.1086/650749.
7. Chun TW, Fauci AS. 2012. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS 26:1261-1268. http://dx.doi.org/10.1097/QAD.0b013e328353f3f1.
8. Smith MZ, Wightman F, Lewin SR. 2012. HIV reservoirs and strategies for eradication. Curr HIV/AIDS Rep 9:5-15. http://dx.doi.org/10.1007/s11904-011-0108-2.
9. 4+ T-cell memory and HIV persistence: keeping memory, keeping HIV. Curr Opin HIV AIDS 6:30-36. http://dx.doi.org/10.1097/COH.0b013e3283413775.
10. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy JP, Haddad EK, Sekaly RP. 2009. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15:893-900. http://dx.doi.org/10.1038/nm.1972.
11. 4+ T cells with stem cell-like properties. Nat Med 20:139-142. http://dx.doi.org/10.1038/nm.3445.
12. Perreau M, Savoye AL, De Crignis E, Corpataux JM, Cubas R, Haddad EK, De Leval L, Graziosi C, Pantaleo G. 2013. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med 210:143-156. http://dx.doi.org/10.1084/jem.20121932.
13. Vinuesa CG. 2012. HIV and T follicular helper cells: a dangerous relationship. J Clin Invest 122:3059-3062. http://dx.doi.org/10.1172/JCI65175.
14. Lindqvist M, van Lunzen J, Soghoian DZ, Kuhl BD, Ranasinghe S, Kranias G, Flanders MD, Cutler S, Yudanin N, Muller MI, Davis I, Farber D, Hartjen P, Haag F, Alter G, Schulze zur Wiesch J, Streeck H. 2012. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J Clin Invest 122:3271-3280. http://dx.doi.org/10.1172/JCI64314.
15. 4+ T cells and lymphoid tissue viral burden distinguish progressive and nonprogressive lentiviral infections. Blood 120:4172-4181. http://dx.doi.org/10.1182/blood-2012-06-437608.
16. Fukazawa Y, Park H, Cameron MJ, Lefebvre F, Lum R, Coombes N, Mahyari E, Hagen SI, Bae JY, Reyes MD, III, Swanson T, Legasse AW, Sylwester A, Hansen SG, Smith AT, Stafova P, Shoemaker R, Li Y, Oswald K, Axthelm MK, McDermott A, Ferrari G, Montefiori DC, Edlefsen PT, Piatak M, Jr, Lifson JD, Sekaly RP, Picker LJ. 2012. Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nat Med 18:1673-1681. http://dx.doi.org/10.1038/nm.2934.
17. Klatt NR, Vinton CL, Lynch RM, Canary LA, Ho J, Darrah PA, Estes JD, Seder RA, Moir SL, Brenchley JM. 2011. SIV infection of rhesus macaques results in dysfunctional T-and B-cell responses to neo and recall Leishmania major vaccination. Blood 118:5803-5812. http://dx.doi.org/10.1182/blood-2011-07-365874.
18. Petrovas C, Yamamoto T, Gerner MY, Boswell KL, Wloka K, Smith EC, Ambrozak DR, Sandler NG, Timmer KJ, Sun X, Pan L, Poholek A, Rao SS, Brenchley JM, Alam SM, Tomaras GD, Roederer M, Douek DC, Seder RA, Germain RN, Haddad EK, Koup RA. 2012. CD4 T follicular helper cell dynamics during SIV infection. J Clin Invest 122:3281-3294. http://dx.doi.org/10.1172/JCI63039.
19. Fukazawa Y, Lum R, Okoye AA, Park H, Matsuda K, Bae JY, Hagen SI, Shoemaker R, Deleage C, Lucero C, Morcock D, Swanson T, Legasse AW, Axthelm MK, Hesselgesser J, Geleziunas R, Hirsch VM, Edlefsen PT, Piatak M, Jr, Estes JD, Lifson JD, Picker LJ. 2015. B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat Med 21:132-139. http://dx.doi.org/10.1038/nm.3781.
20. 4+ T cells depends on chemokine-induced changes in the actin cytoskeleton. Proc Natl Acad Sci U S A 107:16934-16939. http://dx.doi.org/10.1073/pnas.1002894107.
21. 4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood 110:4161-4164. http://dx.doi.org/10.1182/blood-2007-06-097907.
22. Chevalier N, Jarrossay D, Ho E, Avery DT, Ma CS, Yu D, Sallusto F, Tangye SG, Mackay CR. 2011. CXCR5 expressing human central memory CD4 T cells and their relevance for humoral immune responses. J Immunol 186:5556-5568. http://dx.doi.org/10.4049/jimmunol.1002828.
23. Morita R, Schmitt N, Bentebibel SE, Ranganathan R, Bourdery L, Zurawski G, Foucat E, Dullaers M, Oh S, Sabzghabaei N, Lavecchio EM, Punaro M, Pascual V, Banchereau J, Ueno H. 2011. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity 34:108-121. http://dx.doi.org/10.1016/j.immuni.2010.12.012.
24. Vinuesa CG, Cook MC. 2011. Blood relatives of follicular helper T cells. Immunity 34:10-12. http://dx.doi.org/10.1016/j.immuni.2011.01.006.
25. Crotty S. 2011. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 29:621-663. http://dx.doi.org/10.1146/annurev-immunol-031210-101400.
26. Sage PT, Alvarez D, Godec J, von Andrian UH, Sharpe AH. 2014. Circulating T follicular regulatory and helper cells have memory-like properties. J Clin Invest 124:5191-5204. http://dx.doi.org/10.1172/JCI76861.
27. Tsai LM, Yu D. 2014. Follicular helper T-cell memory: establishing new frontiers during antibody response. Immunol Cell Biol 92:57-63. http://dx.doi.org/10.1038/icb.2013.68.
28. Pallikkuth S, Fischl MA, Pahwa S. 2013. Combination antiretroviral therapy with raltegravir leads to rapid immunologic reconstitution in treatment-naive patients with chronic HIV infection. J Infect Dis 208: 1613-1623. http://dx.doi.org/10.1093/infdis/jit387.
29. HIV AIDS Network Coordination (hanc). 3 October 2011. Cross-network PBMC processing SOP v4.0. https://www.hanc.info/labs/Documents/HANC-LAB-0001_v4.0_2011-10-03_PBMC%20SOP.pdf. Accessed 5 March 2012.
30. Boyum A. 1968. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl 97:77-89.
31. Gupta S, Termini JM, Niu L, Kanagavelu SK, Schmidtmayerova H, Snarsky V, Kornbluth RS, Stone GW. 2011. EBV LMP1, a viral mimic of CD40, activates dendritic cells and functions as a molecular adjuvant when incorporated into an HIV vaccine. J Leukoc Biol 90:389-398. http://dx.doi.org/10.1189/jlb.0211068.
32. Maecker HT, Trotter J. 2006. Flow cytometry controls, instrument setup, and the determination of positivity. Cytometry A 69:1037-1042.
33. Perfetto SP, Ambrozak D, Nguyen R, Chattopadhyay P, Roederer M. 2006. Quality assurance for polychromatic flow cytometry. Nat Protoc 1:1522-1530. http://dx.doi.org/10.1038/nprot.2006.250.
34. Lassen KG, Hebbeler AM, Bhattacharyya D, Lobritz MA, Greene WC. 2012. A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs. PLoS One 7:e30176. http://dx.doi.org/10.1371/journal.pone.0030176.
35. Mascola JR, Louder MK, Winter C, Prabhakara R, De Rosa SC, Douek DC, Hill BJ, Gabuzda D, Roederer M. 2002. Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells. J Virol 76:4810-4821. http://dx.doi.org/10.1128/JVI.76.10.4810-4821.2002.
36. 4+ T cells. Retrovirology 8:80. http://dx.doi.org/10.1186/1742-4690-8-80.
37. Sharkey M, Babic DZ, Greenough T, Gulick R, Kuritzkes DR, Stevenson M. 2011. Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. PLoS Pathog 7:e1001303. http://dx.doi.org/10.1371/journal.ppat.1001303.
38. Sharkey ME, Teo I, Greenough T, Sharova N, Luzuriaga K, Sullivan JL, Bucy RP, Kostrikis LG, Haase A, Veryard C, Davaro RE, Cheeseman SH, Daly JS, Bova C, Ellison RT, III, Mady B, Lai KK, Moyle G, Nelson M, Gazzard B, Shaunak S, Stevenson M. 2000. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med 6:76-81. http://dx.doi.org/10.1038/71569.
39. Fazilleau N, Mark L, McHeyzer-Williams LJ, McHeyzer-Williams MG. 2009. Follicular helper T cells: lineage and location. Immunity 30:324-335. http://dx.doi.org/10.1016/j.immuni.2009.03.003.
40. Xu Y, Weatherall C, Bailey M, Alcantara S, De Rose R, Estaquier J, Wilson K, Suzuki K, Corbeil J, Cooper DA, Kent SJ, Kelleher AD, Zaunders J. 2013. Simian immunodeficiency virus infects follicular helper CD4 T cells in lymphoid tissues during pathogenic infection of pigtail macaques. J Virol 87:3760-3773. http://dx.doi.org/10.1128/JVI.02497-12.
41. Pallikkuth S, Parmigiani A, Silva SY, George VK, Fischl M, Pahwa R, Pahwa S. 2012. Impaired peripheral blood T-follicular helper cell function in HIV-infected non-responders to the 2009 H1N1/09 vaccine. Blood 120:985-993. http://dx.doi.org/10.1182/blood-2011-12-396648.
42. Suan D, Nguyen A, Moran I, Bourne K, Hermes JR, Arshi M, Hampton HR, Tomura M, Miwa Y, Kelleher AD, Kaplan W, Deenick EK, Tangye SG, Brink R, Chtanova T, Phan TG. 2015. T follicular helper cells have distinct modes of migration and molecular signatures in naive and memory immune responses. Immunity 42:704-718. http://dx.doi.org/10.1016/j.immuni.2015.03.002.
43. Sharkey M, Triques K, Kuritzkes DR, Stevenson M. 2005. In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol 79:5203-5210. http://dx.doi.org/10.1128/JVI.79.8.5203-5210.2005.
44. Viard JP, Burgard M, Hubert JB, Aaron L, Rabian C, Pertuiset N, Lourenco M, Rothschild C, Rouzioux C. 2004. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS 18:45-49. http://dx.doi.org/10.1097/00002030-200401020-00005.
45. Hocqueloux L, Avettand-Fenoel V, Jacquot S, Prazuck T, Legac E, Melard A, Niang M, Mille C, Le Moal G, Viard JP, Rouzioux C. 2013. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother 68:1169-1178. http://dx.doi.org/10.1093/jac/dks533.
46. Laanani M, Ghosn J, Essat A, Melard A, Seng R, Gousset M, Panjo H, Mortier E, Girard PM, Goujard C, Meyer L, Rouzioux C. 2015. Impact of the timing of initiation of antiretroviral therapy during primary HIV-1 infection on the decay of cell-associated HIV-DNA. Clin Infect Dis 60: 1715-1721. http://dx.doi.org/10.1093/cid/civ171.
47. Chéret A, Bacchus C, Mélard A, Nembot G, Blanc C, Samri A, Avettand-Fenoël V, SaezCirion A, Autran B, Rouzioux C, OPTIPRIM ANRS-147 Study Group. 2014. Early HAART in primary HIV infection protects TCD4 central memory cells and can induce HIV remission, poster 398. In 21st Conf Retroviruses Opportunistic Infect (CROI), Boston, MA, 3 to 6 March 2014. http://croi2014.org/sites/default/files/uploads/CROI2014_Final_Abstracts.pdf.
48. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, Lai J, Blankson JN, Siliciano JD, Siliciano RF. 2013. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155:540-551. http://dx.doi.org/10.1016/j.cell.2013.09.020.
49. Buzón MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, Gatell JM, Domingo P, Paredes R, Sharkey M, Palmer S, Stevenson M, Clotet B, Blanco J, Martinez-Picado J. 2010. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAARTsuppressed subjects. Nat Med 16:460-465. http://dx.doi.org/10.1038/nm.2111.
50. Llibre JM, Buzon MJ, Massanella M, Esteve A, Dahl V, Puertas MC, Domingo P, Gatell JM, Larrouse M, Gutierrez M, Palmer S, Stevenson M, Blanco J, Martinez-Picado J, Clotet B. 2012. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther 17:355-364.
51. Shete A, Thakar M, Singh DP, Gangakhedkar R, Gaikwad A, Pawar J, Paranjape R. 2012. Short communication: HIV antigen-specific reactivation of HIV infection from cellular reservoirs: implications in the settings of therapeutic vaccinations. AIDS Res Hum Retroviruses 28:835-843. http://dx.doi.org/10.1089/aid.2010.0363.
52. Bruner KM, Hosmane NN, Siliciano RF. 2015. Towards an HIV-1 cure: measuring the latent reservoir. Trends Microbiol 23:192-203. http://dx.doi.org/10.1016/j.tim.2015.01.013.
53. Rosenbloom DI, Elliott O, Hill AL, Henrich TJ, Siliciano JM, Siliciano RF. 2015. Designing and interpreting limiting dilution assays: general principles and applications to the latent reservoir for human immunodeficiency virus-1. Open Forum Infect Dis 2:ofv123. http://dx.doi.org/10.1093/ofid/ofv123.
54. Vallejo A, Gutierrez C, Hernandez-Novoa B, Diaz L, Madrid N, Abad-Fernandez M, Dronda F, Perez-Elias MJ, Zamora J, Munoz E, Munoz-Fernandez MA, Moreno S. 2012. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients. AIDS 26:1885-1894. http://dx.doi.org/10.1097/QAD.0b013e3283584521.
55. Lambotte O, Demoustier A, de Goer MG, Wallon C, Gasnault J, Goujard C, Delfraissy JF, Taoufik Y. 2002. Persistence of replicationcompetent HIV in both memory and naive CD4 T cell subsets in patients on prolonged and effective HAART. AIDS 16:2151-2157. http://dx.doi.org/10.1097/00002030-200211080-00007.
56. DaFonseca S, Chomont N, El Far M, Boulassel R, Routy J, Sékaly R. 2010. Purging the HIV-1 reservoir through the disruption of the PD-1 pathway. J Int AIDS Soc 13:O15. http://dx.doi.org/10.1186/1758-2652-13-S3-O15.